Tyr-TGFα transgenic mice develop ocular melanocytic lesions

Melanoma Research

Volumn 12, Issue 5, 2002, Pages 435-439

  Sutton, R ^a   Gordon Thomson, C ^a   Cree, I A ^a   Mason, R S ^a   Moore, G P M ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Melanocyte; Ocular lesion; TGF ; Transgenic mouse

Indexed keywords

COMPLEMENTARY DNA; MONOPHENOL MONOOXYGENASE; TRANSFORMING GROWTH FACTOR ALPHA; TYROSYL TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL HYPERPLASIA; CELL MIGRATION; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CHOROID; CHOROID MELANOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; EYE TUMOR; GENE TRANSFER; HARDER GLAND; HEAD; LATENT PERIOD; MELANOCYTE; MICROINJECTION; MOUSE; NERVOUS TISSUE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; SKELETAL MUSCLE; SKIN TUMOR; TRANSGENIC MOUSE; TUMOR GROWTH; ANIMAL; BIOLOGICAL MODEL; EYE; GENETICS; MELANOMA; METABOLISM; TISSUE DISTRIBUTION; TRANSGENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EYE; EYE NEOPLASMS; MELANOCYTES; MELANOMA; MICE; MICE, TRANSGENIC; MODELS, GENETIC; MONOPHENOL MONOOXYGENASE; PROMOTER REGIONS (GENETICS); TISSUE DISTRIBUTION; TRANSFORMING GROWTH FACTOR ALPHA; TRANSGENES;

EID: 1842847289     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200209000-00004     Document Type: Article

References (23)

1. Ellem KAO, Cullinan M, Baumann KC, Dunstan A. UVR induction of TGFα: A possible autocrine mechanism for the epidermal melanocytic response and for promotion of epidermal carcinogenesis. Carcinogenesis 1988; 9: 797-801.
2. Vasser R, Fuchs E. Transgenic mice provide insights into the role of TGFα during epidermal development and differentiation. Genes Dev 1991; 5: 714-727.
3. Matsui Y, Halter SA, Holt JT, Hogan BLM, Coffey RJ. Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice. Cell 1990; 61: 1147-1155.
4. Marquardt H, Todaro GJ. Human transforming growth factor. Production by a melanoma cell line, purification, and initial characterisation. J Biol Chem 1982; 257: 5220-5225.
5. Nanney LB, Coffey R, Ellis DL. Expression and distribution of transforming growth factor-α within melanocytic lesions. J Invest Dermatol 1994; 103: 707-714.
6. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994; 56: 853-857.
7. Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross A, Nowell P. Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet 1985; 11: 297-302.
8. Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, et al. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 1989; 49: 5091-5096.
9. de Wit PEJ, Moretti S, Koenders PG, Weterman MAJ, van Muijen GNP, Gianotti B, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 1992; 99: 168-173.
10. Ma D, Niederkorn JY. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas. Invest Ophthalmol Vis Sci 1998; 39: 1067-1075.
11. Gordon-Thomson C, Mason RS, Moore GPM. Regulation of epidermal growth factor receptor expression in human melanocytes. Exp Dermatol 2001; 10: 321-328.
12. Beermann F, Schmid E, Schütz G. Expression of the mouse tyrosinase gene during embryonic development: Recapitulation of the temporal regulation in transgenic mice. Proc Natl Acad Sci USA 1992; 89: 2809-2813.
13. Ganss R, Montoliu L, Monaghan AP, Schutz G. A cellspecific enhancer far upstream of the mouse tyrosinase gene confers high level and copy number-related expression in transgenic mice. EMBO J 1994; 13: 3083-3093.
14. Jhappen CC, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT. TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990; 61: 1137-1146.
15. Bradl M, Klein-Szanto A, Porter S, Mintz B. Malignant melanoma in transgenic mice. Proc Natl Acad Sci USA 1991; 88: 164-168.
16. Powell MB, Hyman P, Bell DO, Balmain A, Brown K, Alberts D, et al. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol Carcinog 1995; 12: 82-90.
17. Markert CL, Silvers WK. The effects of genotype and cell environment on melanoblast differentiation in the house mouse. Genetics 1956; 41: 429-450.
18. Grin JM, Grant-Kels JM, Grin CM, Berke A, Kels BD. Ocular melanomas and melanocytic lesions of the eye. J Am Acad Dermatol 1998; 38: 716-730.
19. Cather JC, Soparkar CN, Nelson BR. Ocular melanoma, Cutis 1999; 63: 285-292.
20. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643.
21. Kramer TR, Powell MB, Wilson MM, Salvatore J, Grossniklaus HE. Pigmented uveal tumors in a transgenic mouse model. Br J Ophthalmol 1998; 82: 953-960.
22. Larue L, Dougherty N, Bradl M, Mintz B. Melanocyte culture lines from Tyr-SV40E transgenic mice: Models for the molecular genetic evolution of malignant melanoma. Oncogene 1993; 8: 523-531.
23. Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, et al. Autocrine interaction between TGFα and the EGF-receptor: Quantitative requirements for induction of the malignant phenotype. Oncogene 1989; 4: 831-838.